nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—ABCB1—ovarian cancer	0.21	1	CbGaD
Buprenorphine—ABCG2—Topotecan—ovarian cancer	0.0842	0.149	CbGbCtD
Buprenorphine—ABCG2—Paclitaxel—ovarian cancer	0.0417	0.0736	CbGbCtD
Buprenorphine—ABCG2—Carboplatin—ovarian cancer	0.0392	0.0693	CbGbCtD
Buprenorphine—CYP3A7—Paclitaxel—ovarian cancer	0.0308	0.0544	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.0308	0.0544	CbGbCtD
Buprenorphine—ABCB1—Topotecan—ovarian cancer	0.0304	0.0536	CbGbCtD
Buprenorphine—ABCG2—Docetaxel—ovarian cancer	0.0301	0.0532	CbGbCtD
Buprenorphine—CYP3A5—Paclitaxel—ovarian cancer	0.0231	0.0408	CbGbCtD
Buprenorphine—ABCG2—Doxorubicin—ovarian cancer	0.0225	0.0397	CbGbCtD
Buprenorphine—CYP3A7—Docetaxel—ovarian cancer	0.0223	0.0393	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.0223	0.0393	CbGbCtD
Buprenorphine—CYP2C8—Paclitaxel—ovarian cancer	0.0222	0.0392	CbGbCtD
Buprenorphine—ABCB1—Vinorelbine—ovarian cancer	0.0214	0.0378	CbGbCtD
Buprenorphine—CYP2D6—Vinorelbine—ovarian cancer	0.0202	0.0356	CbGbCtD
Buprenorphine—CYP3A4—Topotecan—ovarian cancer	0.0182	0.0321	CbGbCtD
Buprenorphine—CYP3A5—Docetaxel—ovarian cancer	0.0167	0.0295	CbGbCtD
Buprenorphine—CYP2C9—Paclitaxel—ovarian cancer	0.0155	0.0274	CbGbCtD
Buprenorphine—ABCB1—Paclitaxel—ovarian cancer	0.015	0.0265	CbGbCtD
Buprenorphine—CYP3A4—Vinorelbine—ovarian cancer	0.0128	0.0226	CbGbCtD
Buprenorphine—ABCB1—Docetaxel—ovarian cancer	0.0109	0.0192	CbGbCtD
Buprenorphine—CYP3A4—Paclitaxel—ovarian cancer	0.009	0.0159	CbGbCtD
Buprenorphine—ABCB1—Doxorubicin—ovarian cancer	0.0081	0.0143	CbGbCtD
Buprenorphine—CYP2D6—Doxorubicin—ovarian cancer	0.00763	0.0135	CbGbCtD
Buprenorphine—CYP3A4—Docetaxel—ovarian cancer	0.00651	0.0115	CbGbCtD
Buprenorphine—CYP3A4—Doxorubicin—ovarian cancer	0.00485	0.00857	CbGbCtD
Buprenorphine—Naloxone—TLR4—ovarian cancer	0.00297	0.64	CrCbGaD
Buprenorphine—OPRL1—female reproductive system—ovarian cancer	0.000878	0.0911	CbGeAlD
Buprenorphine—Naloxone—ESR1—ovarian cancer	0.000834	0.179	CrCbGaD
Buprenorphine—OPRL1—testis—ovarian cancer	0.000709	0.0735	CbGeAlD
Buprenorphine—CYP2C18—uterine cervix—ovarian cancer	0.000668	0.0693	CbGeAlD
Buprenorphine—OPRL1—lymph node—ovarian cancer	0.000514	0.0533	CbGeAlD
Buprenorphine—Naltrexone—ABCB1—ovarian cancer	0.000486	0.105	CrCbGaD
Buprenorphine—CYP2C18—vagina—ovarian cancer	0.000452	0.0469	CbGeAlD
Buprenorphine—OPRK1—female reproductive system—ovarian cancer	0.000434	0.045	CbGeAlD
Buprenorphine—Naloxone—ABCB1—ovarian cancer	0.000354	0.0762	CrCbGaD
Buprenorphine—ABCG2—myometrium—ovarian cancer	0.000309	0.0321	CbGeAlD
Buprenorphine—CYP2A6—vagina—ovarian cancer	0.000299	0.031	CbGeAlD
Buprenorphine—OPRM1—testis—ovarian cancer	0.000249	0.0258	CbGeAlD
Buprenorphine—ABCG2—uterine cervix—ovarian cancer	0.000241	0.025	CbGeAlD
Buprenorphine—ABCG2—decidua—ovarian cancer	0.000229	0.0238	CbGeAlD
Buprenorphine—CYP2C8—endometrium—ovarian cancer	0.000224	0.0232	CbGeAlD
Buprenorphine—CYP3A5—uterine cervix—ovarian cancer	0.000224	0.0232	CbGeAlD
Buprenorphine—ABCG2—endometrium—ovarian cancer	0.000218	0.0226	CbGeAlD
Buprenorphine—ABCG2—uterus—ovarian cancer	0.000201	0.0208	CbGeAlD
Buprenorphine—CYP2C19—vagina—ovarian cancer	0.000192	0.02	CbGeAlD
Buprenorphine—CYP2C8—female reproductive system—ovarian cancer	0.000186	0.0193	CbGeAlD
Buprenorphine—ABCG2—bone marrow—ovarian cancer	0.00017	0.0177	CbGeAlD
Buprenorphine—CYP2C8—vagina—ovarian cancer	0.000168	0.0174	CbGeAlD
Buprenorphine—CYP2C9—female reproductive system—ovarian cancer	0.000165	0.0171	CbGeAlD
Buprenorphine—ABCG2—female gonad—ovarian cancer	0.000164	0.017	CbGeAlD
Buprenorphine—ABCG2—vagina—ovarian cancer	0.000163	0.0169	CbGeAlD
Buprenorphine—Weight decreased—Epirubicin—ovarian cancer	0.000153	0.000867	CcSEcCtD
Buprenorphine—ABCB1—myometrium—ovarian cancer	0.000153	0.0158	CbGeAlD
Buprenorphine—CYP3A5—female gonad—ovarian cancer	0.000152	0.0158	CbGeAlD
Buprenorphine—Cough—Docetaxel—ovarian cancer	0.000152	0.000864	CcSEcCtD
Buprenorphine—Angina pectoris—Doxorubicin—ovarian cancer	0.000152	0.000864	CcSEcCtD
Buprenorphine—Insomnia—Paclitaxel—ovarian cancer	0.000152	0.000862	CcSEcCtD
Buprenorphine—CYP3A5—vagina—ovarian cancer	0.000151	0.0157	CbGeAlD
Buprenorphine—Convulsion—Docetaxel—ovarian cancer	0.000151	0.000858	CcSEcCtD
Buprenorphine—Paraesthesia—Paclitaxel—ovarian cancer	0.000151	0.000856	CcSEcCtD
Buprenorphine—Hypertension—Docetaxel—ovarian cancer	0.000151	0.000855	CcSEcCtD
Buprenorphine—Infestation NOS—Epirubicin—ovarian cancer	0.000151	0.000855	CcSEcCtD
Buprenorphine—Infestation—Epirubicin—ovarian cancer	0.000151	0.000855	CcSEcCtD
Buprenorphine—Bronchitis—Doxorubicin—ovarian cancer	0.00015	0.000853	CcSEcCtD
Buprenorphine—CYP2C8—testis—ovarian cancer	0.00015	0.0155	CbGeAlD
Buprenorphine—Dyspnoea—Paclitaxel—ovarian cancer	0.00015	0.00085	CcSEcCtD
Buprenorphine—Somnolence—Paclitaxel—ovarian cancer	0.000149	0.000848	CcSEcCtD
Buprenorphine—Chest pain—Docetaxel—ovarian cancer	0.000149	0.000843	CcSEcCtD
Buprenorphine—Myalgia—Docetaxel—ovarian cancer	0.000149	0.000843	CcSEcCtD
Buprenorphine—Arthralgia—Docetaxel—ovarian cancer	0.000149	0.000843	CcSEcCtD
Buprenorphine—Nausea—Vinorelbine—ovarian cancer	0.000148	0.000842	CcSEcCtD
Buprenorphine—Dyspepsia—Paclitaxel—ovarian cancer	0.000148	0.000839	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000147	0.000837	CcSEcCtD
Buprenorphine—ABCB1—embryo—ovarian cancer	0.000147	0.0152	CbGeAlD
Buprenorphine—Conjunctivitis—Epirubicin—ovarian cancer	0.000146	0.000831	CcSEcCtD
Buprenorphine—Urinary tract infection—Epirubicin—ovarian cancer	0.000146	0.000831	CcSEcCtD
Buprenorphine—Decreased appetite—Paclitaxel—ovarian cancer	0.000146	0.000829	CcSEcCtD
Buprenorphine—ABCG2—testis—ovarian cancer	0.000146	0.0151	CbGeAlD
Buprenorphine—Dry mouth—Docetaxel—ovarian cancer	0.000145	0.000825	CcSEcCtD
Buprenorphine—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000145	0.000824	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000145	0.000823	CcSEcCtD
Buprenorphine—Fatigue—Paclitaxel—ovarian cancer	0.000145	0.000822	CcSEcCtD
Buprenorphine—Sweating—Epirubicin—ovarian cancer	0.000144	0.000819	CcSEcCtD
Buprenorphine—Constipation—Paclitaxel—ovarian cancer	0.000144	0.000815	CcSEcCtD
Buprenorphine—Pain—Paclitaxel—ovarian cancer	0.000144	0.000815	CcSEcCtD
Buprenorphine—Confusional state—Docetaxel—ovarian cancer	0.000144	0.000815	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000142	0.000808	CcSEcCtD
Buprenorphine—Anaphylactic shock—Docetaxel—ovarian cancer	0.000142	0.000808	CcSEcCtD
Buprenorphine—Oedema—Docetaxel—ovarian cancer	0.000142	0.000808	CcSEcCtD
Buprenorphine—Infection—Docetaxel—ovarian cancer	0.000141	0.000803	CcSEcCtD
Buprenorphine—Weight decreased—Doxorubicin—ovarian cancer	0.000141	0.000803	CcSEcCtD
Buprenorphine—Sinusitis—Epirubicin—ovarian cancer	0.000141	0.000802	CcSEcCtD
Buprenorphine—Shock—Docetaxel—ovarian cancer	0.00014	0.000795	CcSEcCtD
Buprenorphine—Nervous system disorder—Docetaxel—ovarian cancer	0.00014	0.000793	CcSEcCtD
Buprenorphine—Infestation NOS—Doxorubicin—ovarian cancer	0.000139	0.000791	CcSEcCtD
Buprenorphine—Infestation—Doxorubicin—ovarian cancer	0.000139	0.000791	CcSEcCtD
Buprenorphine—Tachycardia—Docetaxel—ovarian cancer	0.000139	0.000789	CcSEcCtD
Buprenorphine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000138	0.000786	CcSEcCtD
Buprenorphine—Skin disorder—Docetaxel—ovarian cancer	0.000138	0.000785	CcSEcCtD
Buprenorphine—Bradycardia—Epirubicin—ovarian cancer	0.000138	0.000781	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000137	0.00078	CcSEcCtD
Buprenorphine—Anorexia—Docetaxel—ovarian cancer	0.000136	0.00077	CcSEcCtD
Buprenorphine—Rhinitis—Epirubicin—ovarian cancer	0.000136	0.000769	CcSEcCtD
Buprenorphine—Conjunctivitis—Doxorubicin—ovarian cancer	0.000135	0.000769	CcSEcCtD
Buprenorphine—Urinary tract infection—Doxorubicin—ovarian cancer	0.000135	0.000769	CcSEcCtD
Buprenorphine—Hypoaesthesia—Epirubicin—ovarian cancer	0.000134	0.000763	CcSEcCtD
Buprenorphine—Pharyngitis—Epirubicin—ovarian cancer	0.000134	0.000762	CcSEcCtD
Buprenorphine—Sweating—Doxorubicin—ovarian cancer	0.000134	0.000758	CcSEcCtD
Buprenorphine—Urinary tract disorder—Epirubicin—ovarian cancer	0.000133	0.000758	CcSEcCtD
Buprenorphine—Urticaria—Paclitaxel—ovarian cancer	0.000133	0.000758	CcSEcCtD
Buprenorphine—Oedema peripheral—Epirubicin—ovarian cancer	0.000133	0.000756	CcSEcCtD
Buprenorphine—Hypotension—Docetaxel—ovarian cancer	0.000133	0.000755	CcSEcCtD
Buprenorphine—Connective tissue disorder—Epirubicin—ovarian cancer	0.000133	0.000754	CcSEcCtD
Buprenorphine—Body temperature increased—Paclitaxel—ovarian cancer	0.000133	0.000754	CcSEcCtD
Buprenorphine—Abdominal pain—Paclitaxel—ovarian cancer	0.000133	0.000754	CcSEcCtD
Buprenorphine—Urethral disorder—Epirubicin—ovarian cancer	0.000132	0.000752	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000132	0.000748	CcSEcCtD
Buprenorphine—Sinusitis—Doxorubicin—ovarian cancer	0.000131	0.000742	CcSEcCtD
Buprenorphine—Visual impairment—Epirubicin—ovarian cancer	0.00013	0.000739	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.00013	0.000736	CcSEcCtD
Buprenorphine—Insomnia—Docetaxel—ovarian cancer	0.000129	0.000731	CcSEcCtD
Buprenorphine—Paraesthesia—Docetaxel—ovarian cancer	0.000128	0.000726	CcSEcCtD
Buprenorphine—Bradycardia—Doxorubicin—ovarian cancer	0.000127	0.000723	CcSEcCtD
Buprenorphine—Dyspnoea—Docetaxel—ovarian cancer	0.000127	0.000721	CcSEcCtD
Buprenorphine—Somnolence—Docetaxel—ovarian cancer	0.000127	0.000719	CcSEcCtD
Buprenorphine—Eye disorder—Epirubicin—ovarian cancer	0.000126	0.000717	CcSEcCtD
Buprenorphine—Tinnitus—Epirubicin—ovarian cancer	0.000126	0.000715	CcSEcCtD
Buprenorphine—CYP3A4—female reproductive system—ovarian cancer	0.000126	0.013	CbGeAlD
Buprenorphine—Flushing—Epirubicin—ovarian cancer	0.000125	0.000712	CcSEcCtD
Buprenorphine—Cardiac disorder—Epirubicin—ovarian cancer	0.000125	0.000712	CcSEcCtD
Buprenorphine—Rhinitis—Doxorubicin—ovarian cancer	0.000125	0.000712	CcSEcCtD
Buprenorphine—Dyspepsia—Docetaxel—ovarian cancer	0.000125	0.000711	CcSEcCtD
Buprenorphine—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000124	0.000706	CcSEcCtD
Buprenorphine—Pharyngitis—Doxorubicin—ovarian cancer	0.000124	0.000705	CcSEcCtD
Buprenorphine—Decreased appetite—Docetaxel—ovarian cancer	0.000124	0.000703	CcSEcCtD
Buprenorphine—Hypersensitivity—Paclitaxel—ovarian cancer	0.000124	0.000703	CcSEcCtD
Buprenorphine—CYP2D6—female reproductive system—ovarian cancer	0.000124	0.0128	CbGeAlD
Buprenorphine—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000124	0.000701	CcSEcCtD
Buprenorphine—Oedema peripheral—Doxorubicin—ovarian cancer	0.000123	0.000699	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000123	0.000698	CcSEcCtD
Buprenorphine—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000123	0.000698	CcSEcCtD
Buprenorphine—Fatigue—Docetaxel—ovarian cancer	0.000123	0.000697	CcSEcCtD
Buprenorphine—Angiopathy—Epirubicin—ovarian cancer	0.000123	0.000696	CcSEcCtD
Buprenorphine—Urethral disorder—Doxorubicin—ovarian cancer	0.000123	0.000696	CcSEcCtD
Buprenorphine—Immune system disorder—Epirubicin—ovarian cancer	0.000122	0.000693	CcSEcCtD
Buprenorphine—Mediastinal disorder—Epirubicin—ovarian cancer	0.000122	0.000692	CcSEcCtD
Buprenorphine—Pain—Docetaxel—ovarian cancer	0.000122	0.000691	CcSEcCtD
Buprenorphine—Constipation—Docetaxel—ovarian cancer	0.000122	0.000691	CcSEcCtD
Buprenorphine—Chills—Epirubicin—ovarian cancer	0.000121	0.000689	CcSEcCtD
Buprenorphine—Visual impairment—Doxorubicin—ovarian cancer	0.000121	0.000684	CcSEcCtD
Buprenorphine—Asthenia—Paclitaxel—ovarian cancer	0.000121	0.000684	CcSEcCtD
Buprenorphine—ABCB1—epithelium—ovarian cancer	0.00012	0.0124	CbGeAlD
Buprenorphine—Pruritus—Paclitaxel—ovarian cancer	0.000119	0.000675	CcSEcCtD
Buprenorphine—ABCB1—uterine cervix—ovarian cancer	0.000119	0.0123	CbGeAlD
Buprenorphine—Mental disorder—Epirubicin—ovarian cancer	0.000118	0.000672	CcSEcCtD
Buprenorphine—Erythema—Epirubicin—ovarian cancer	0.000118	0.000668	CcSEcCtD
Buprenorphine—Malnutrition—Epirubicin—ovarian cancer	0.000118	0.000668	CcSEcCtD
Buprenorphine—Feeling abnormal—Docetaxel—ovarian cancer	0.000117	0.000666	CcSEcCtD
Buprenorphine—Eye disorder—Doxorubicin—ovarian cancer	0.000117	0.000664	CcSEcCtD
Buprenorphine—Tinnitus—Doxorubicin—ovarian cancer	0.000117	0.000662	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000116	0.000661	CcSEcCtD
Buprenorphine—Cardiac disorder—Doxorubicin—ovarian cancer	0.000116	0.000659	CcSEcCtD
Buprenorphine—Flushing—Doxorubicin—ovarian cancer	0.000116	0.000659	CcSEcCtD
Buprenorphine—Flatulence—Epirubicin—ovarian cancer	0.000116	0.000658	CcSEcCtD
Buprenorphine—Tension—Epirubicin—ovarian cancer	0.000115	0.000655	CcSEcCtD
Buprenorphine—Dysgeusia—Epirubicin—ovarian cancer	0.000115	0.000654	CcSEcCtD
Buprenorphine—Diarrhoea—Paclitaxel—ovarian cancer	0.000115	0.000652	CcSEcCtD
Buprenorphine—Nervousness—Epirubicin—ovarian cancer	0.000114	0.000649	CcSEcCtD
Buprenorphine—Back pain—Epirubicin—ovarian cancer	0.000114	0.000646	CcSEcCtD
Buprenorphine—Angiopathy—Doxorubicin—ovarian cancer	0.000113	0.000644	CcSEcCtD
Buprenorphine—ABCB1—decidua—ovarian cancer	0.000113	0.0117	CbGeAlD
Buprenorphine—Muscle spasms—Epirubicin—ovarian cancer	0.000113	0.000642	CcSEcCtD
Buprenorphine—Immune system disorder—Doxorubicin—ovarian cancer	0.000113	0.000641	CcSEcCtD
Buprenorphine—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000113	0.00064	CcSEcCtD
Buprenorphine—CYP2D6—female gonad—ovarian cancer	0.000113	0.0117	CbGeAlD
Buprenorphine—Body temperature increased—Docetaxel—ovarian cancer	0.000113	0.000639	CcSEcCtD
Buprenorphine—Abdominal pain—Docetaxel—ovarian cancer	0.000113	0.000639	CcSEcCtD
Buprenorphine—Chills—Doxorubicin—ovarian cancer	0.000112	0.000637	CcSEcCtD
Buprenorphine—Dizziness—Paclitaxel—ovarian cancer	0.000111	0.000631	CcSEcCtD
Buprenorphine—Vision blurred—Epirubicin—ovarian cancer	0.000111	0.00063	CcSEcCtD
Buprenorphine—Mental disorder—Doxorubicin—ovarian cancer	0.00011	0.000622	CcSEcCtD
Buprenorphine—Ill-defined disorder—Epirubicin—ovarian cancer	0.000109	0.00062	CcSEcCtD
Buprenorphine—Erythema—Doxorubicin—ovarian cancer	0.000109	0.000618	CcSEcCtD
Buprenorphine—Malnutrition—Doxorubicin—ovarian cancer	0.000109	0.000618	CcSEcCtD
Buprenorphine—Agitation—Epirubicin—ovarian cancer	0.000108	0.000614	CcSEcCtD
Buprenorphine—ABCB1—endometrium—ovarian cancer	0.000107	0.0111	CbGeAlD
Buprenorphine—Flatulence—Doxorubicin—ovarian cancer	0.000107	0.000609	CcSEcCtD
Buprenorphine—Tension—Doxorubicin—ovarian cancer	0.000107	0.000607	CcSEcCtD
Buprenorphine—Vomiting—Paclitaxel—ovarian cancer	0.000107	0.000606	CcSEcCtD
Buprenorphine—Dysgeusia—Doxorubicin—ovarian cancer	0.000107	0.000605	CcSEcCtD
Buprenorphine—Malaise—Epirubicin—ovarian cancer	0.000106	0.000602	CcSEcCtD
Buprenorphine—Rash—Paclitaxel—ovarian cancer	0.000106	0.000601	CcSEcCtD
Buprenorphine—Dermatitis—Paclitaxel—ovarian cancer	0.000106	0.000601	CcSEcCtD
Buprenorphine—Nervousness—Doxorubicin—ovarian cancer	0.000106	0.0006	CcSEcCtD
Buprenorphine—Vertigo—Epirubicin—ovarian cancer	0.000106	0.0006	CcSEcCtD
Buprenorphine—ABCG2—lymph node—ovarian cancer	0.000106	0.011	CbGeAlD
Buprenorphine—Syncope—Epirubicin—ovarian cancer	0.000106	0.000599	CcSEcCtD
Buprenorphine—Back pain—Doxorubicin—ovarian cancer	0.000105	0.000598	CcSEcCtD
Buprenorphine—Headache—Paclitaxel—ovarian cancer	0.000105	0.000597	CcSEcCtD
Buprenorphine—Hypersensitivity—Docetaxel—ovarian cancer	0.000105	0.000595	CcSEcCtD
Buprenorphine—Muscle spasms—Doxorubicin—ovarian cancer	0.000105	0.000594	CcSEcCtD
Buprenorphine—Palpitations—Epirubicin—ovarian cancer	0.000104	0.00059	CcSEcCtD
Buprenorphine—Loss of consciousness—Epirubicin—ovarian cancer	0.000103	0.000587	CcSEcCtD
Buprenorphine—Cough—Epirubicin—ovarian cancer	0.000103	0.000583	CcSEcCtD
Buprenorphine—Vision blurred—Doxorubicin—ovarian cancer	0.000103	0.000582	CcSEcCtD
Buprenorphine—Asthenia—Docetaxel—ovarian cancer	0.000102	0.00058	CcSEcCtD
Buprenorphine—Convulsion—Epirubicin—ovarian cancer	0.000102	0.000579	CcSEcCtD
Buprenorphine—Hypertension—Epirubicin—ovarian cancer	0.000102	0.000577	CcSEcCtD
Buprenorphine—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000101	0.000573	CcSEcCtD
Buprenorphine—Pruritus—Docetaxel—ovarian cancer	0.000101	0.000572	CcSEcCtD
Buprenorphine—Arthralgia—Epirubicin—ovarian cancer	0.0001	0.000569	CcSEcCtD
Buprenorphine—Myalgia—Epirubicin—ovarian cancer	0.0001	0.000569	CcSEcCtD
Buprenorphine—Chest pain—Epirubicin—ovarian cancer	0.0001	0.000569	CcSEcCtD
Buprenorphine—Agitation—Doxorubicin—ovarian cancer	0.0001	0.000568	CcSEcCtD
Buprenorphine—Anxiety—Epirubicin—ovarian cancer	9.98e-05	0.000567	CcSEcCtD
Buprenorphine—CYP2D6—testis—ovarian cancer	9.98e-05	0.0104	CbGeAlD
Buprenorphine—Nausea—Paclitaxel—ovarian cancer	9.98e-05	0.000566	CcSEcCtD
Buprenorphine—ABCB1—gonad—ovarian cancer	9.96e-05	0.0103	CbGeAlD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	9.95e-05	0.000565	CcSEcCtD
Buprenorphine—ABCB1—uterus—ovarian cancer	9.9e-05	0.0103	CbGeAlD
Buprenorphine—Discomfort—Epirubicin—ovarian cancer	9.9e-05	0.000562	CcSEcCtD
Buprenorphine—Malaise—Doxorubicin—ovarian cancer	9.82e-05	0.000557	CcSEcCtD
Buprenorphine—Dry mouth—Epirubicin—ovarian cancer	9.8e-05	0.000556	CcSEcCtD
Buprenorphine—Vertigo—Doxorubicin—ovarian cancer	9.78e-05	0.000555	CcSEcCtD
Buprenorphine—Syncope—Doxorubicin—ovarian cancer	9.76e-05	0.000554	CcSEcCtD
Buprenorphine—Diarrhoea—Docetaxel—ovarian cancer	9.74e-05	0.000553	CcSEcCtD
Buprenorphine—Confusional state—Epirubicin—ovarian cancer	9.68e-05	0.00055	CcSEcCtD
Buprenorphine—Palpitations—Doxorubicin—ovarian cancer	9.62e-05	0.000546	CcSEcCtD
Buprenorphine—Oedema—Epirubicin—ovarian cancer	9.6e-05	0.000545	CcSEcCtD
Buprenorphine—Anaphylactic shock—Epirubicin—ovarian cancer	9.6e-05	0.000545	CcSEcCtD
Buprenorphine—Loss of consciousness—Doxorubicin—ovarian cancer	9.57e-05	0.000543	CcSEcCtD
Buprenorphine—Infection—Epirubicin—ovarian cancer	9.54e-05	0.000542	CcSEcCtD
Buprenorphine—Cough—Doxorubicin—ovarian cancer	9.5e-05	0.000539	CcSEcCtD
Buprenorphine—Shock—Epirubicin—ovarian cancer	9.45e-05	0.000536	CcSEcCtD
Buprenorphine—Convulsion—Doxorubicin—ovarian cancer	9.43e-05	0.000536	CcSEcCtD
Buprenorphine—Nervous system disorder—Epirubicin—ovarian cancer	9.42e-05	0.000535	CcSEcCtD
Buprenorphine—Dizziness—Docetaxel—ovarian cancer	9.41e-05	0.000534	CcSEcCtD
Buprenorphine—Hypertension—Doxorubicin—ovarian cancer	9.4e-05	0.000534	CcSEcCtD
Buprenorphine—Tachycardia—Epirubicin—ovarian cancer	9.37e-05	0.000532	CcSEcCtD
Buprenorphine—Skin disorder—Epirubicin—ovarian cancer	9.33e-05	0.00053	CcSEcCtD
Buprenorphine—Hyperhidrosis—Epirubicin—ovarian cancer	9.28e-05	0.000527	CcSEcCtD
Buprenorphine—Myalgia—Doxorubicin—ovarian cancer	9.27e-05	0.000526	CcSEcCtD
Buprenorphine—Chest pain—Doxorubicin—ovarian cancer	9.27e-05	0.000526	CcSEcCtD
Buprenorphine—Arthralgia—Doxorubicin—ovarian cancer	9.27e-05	0.000526	CcSEcCtD
Buprenorphine—Anxiety—Doxorubicin—ovarian cancer	9.24e-05	0.000524	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	9.21e-05	0.000523	CcSEcCtD
Buprenorphine—Discomfort—Doxorubicin—ovarian cancer	9.16e-05	0.00052	CcSEcCtD
Buprenorphine—Anorexia—Epirubicin—ovarian cancer	9.15e-05	0.00052	CcSEcCtD
Buprenorphine—Dry mouth—Doxorubicin—ovarian cancer	9.07e-05	0.000515	CcSEcCtD
Buprenorphine—Vomiting—Docetaxel—ovarian cancer	9.05e-05	0.000514	CcSEcCtD
Buprenorphine—Rash—Docetaxel—ovarian cancer	8.98e-05	0.00051	CcSEcCtD
Buprenorphine—Hypotension—Epirubicin—ovarian cancer	8.97e-05	0.000509	CcSEcCtD
Buprenorphine—Dermatitis—Docetaxel—ovarian cancer	8.97e-05	0.000509	CcSEcCtD
Buprenorphine—Confusional state—Doxorubicin—ovarian cancer	8.96e-05	0.000509	CcSEcCtD
Buprenorphine—Headache—Docetaxel—ovarian cancer	8.92e-05	0.000506	CcSEcCtD
Buprenorphine—ABCB1—female reproductive system—ovarian cancer	8.9e-05	0.00923	CbGeAlD
Buprenorphine—Oedema—Doxorubicin—ovarian cancer	8.89e-05	0.000504	CcSEcCtD
Buprenorphine—Anaphylactic shock—Doxorubicin—ovarian cancer	8.89e-05	0.000504	CcSEcCtD
Buprenorphine—Infection—Doxorubicin—ovarian cancer	8.83e-05	0.000501	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	8.75e-05	0.000497	CcSEcCtD
Buprenorphine—Shock—Doxorubicin—ovarian cancer	8.74e-05	0.000496	CcSEcCtD
Buprenorphine—Nervous system disorder—Doxorubicin—ovarian cancer	8.71e-05	0.000495	CcSEcCtD
Buprenorphine—Insomnia—Epirubicin—ovarian cancer	8.69e-05	0.000493	CcSEcCtD
Buprenorphine—Tachycardia—Doxorubicin—ovarian cancer	8.67e-05	0.000492	CcSEcCtD
Buprenorphine—Skin disorder—Doxorubicin—ovarian cancer	8.63e-05	0.00049	CcSEcCtD
Buprenorphine—Paraesthesia—Epirubicin—ovarian cancer	8.62e-05	0.00049	CcSEcCtD
Buprenorphine—Hyperhidrosis—Doxorubicin—ovarian cancer	8.59e-05	0.000488	CcSEcCtD
Buprenorphine—Dyspnoea—Epirubicin—ovarian cancer	8.56e-05	0.000486	CcSEcCtD
Buprenorphine—Somnolence—Epirubicin—ovarian cancer	8.54e-05	0.000485	CcSEcCtD
Buprenorphine—Anorexia—Doxorubicin—ovarian cancer	8.47e-05	0.000481	CcSEcCtD
Buprenorphine—Nausea—Docetaxel—ovarian cancer	8.46e-05	0.00048	CcSEcCtD
Buprenorphine—Dyspepsia—Epirubicin—ovarian cancer	8.45e-05	0.00048	CcSEcCtD
Buprenorphine—ABCB1—bone marrow—ovarian cancer	8.4e-05	0.00872	CbGeAlD
Buprenorphine—Decreased appetite—Epirubicin—ovarian cancer	8.35e-05	0.000474	CcSEcCtD
Buprenorphine—Hypotension—Doxorubicin—ovarian cancer	8.3e-05	0.000471	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Epirubicin—ovarian cancer	8.29e-05	0.000471	CcSEcCtD
Buprenorphine—Fatigue—Epirubicin—ovarian cancer	8.28e-05	0.00047	CcSEcCtD
Buprenorphine—Pain—Epirubicin—ovarian cancer	8.21e-05	0.000466	CcSEcCtD
Buprenorphine—Constipation—Epirubicin—ovarian cancer	8.21e-05	0.000466	CcSEcCtD
Buprenorphine—ABCB1—female gonad—ovarian cancer	8.1e-05	0.0084	CbGeAlD
Buprenorphine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	8.1e-05	0.00046	CcSEcCtD
Buprenorphine—ABCB1—vagina—ovarian cancer	8.05e-05	0.00835	CbGeAlD
Buprenorphine—Insomnia—Doxorubicin—ovarian cancer	8.04e-05	0.000456	CcSEcCtD
Buprenorphine—Paraesthesia—Doxorubicin—ovarian cancer	7.98e-05	0.000453	CcSEcCtD
Buprenorphine—Dyspnoea—Doxorubicin—ovarian cancer	7.92e-05	0.00045	CcSEcCtD
Buprenorphine—Feeling abnormal—Epirubicin—ovarian cancer	7.91e-05	0.000449	CcSEcCtD
Buprenorphine—Somnolence—Doxorubicin—ovarian cancer	7.9e-05	0.000448	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Epirubicin—ovarian cancer	7.85e-05	0.000446	CcSEcCtD
Buprenorphine—Dyspepsia—Doxorubicin—ovarian cancer	7.82e-05	0.000444	CcSEcCtD
Buprenorphine—Decreased appetite—Doxorubicin—ovarian cancer	7.72e-05	0.000438	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	7.67e-05	0.000435	CcSEcCtD
Buprenorphine—Fatigue—Doxorubicin—ovarian cancer	7.66e-05	0.000435	CcSEcCtD
Buprenorphine—Urticaria—Epirubicin—ovarian cancer	7.63e-05	0.000433	CcSEcCtD
Buprenorphine—Pain—Doxorubicin—ovarian cancer	7.6e-05	0.000431	CcSEcCtD
Buprenorphine—Constipation—Doxorubicin—ovarian cancer	7.6e-05	0.000431	CcSEcCtD
Buprenorphine—Abdominal pain—Epirubicin—ovarian cancer	7.59e-05	0.000431	CcSEcCtD
Buprenorphine—Body temperature increased—Epirubicin—ovarian cancer	7.59e-05	0.000431	CcSEcCtD
Buprenorphine—Feeling abnormal—Doxorubicin—ovarian cancer	7.32e-05	0.000416	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Doxorubicin—ovarian cancer	7.27e-05	0.000412	CcSEcCtD
Buprenorphine—ABCB1—testis—ovarian cancer	7.18e-05	0.00745	CbGeAlD
Buprenorphine—Hypersensitivity—Epirubicin—ovarian cancer	7.08e-05	0.000402	CcSEcCtD
Buprenorphine—Urticaria—Doxorubicin—ovarian cancer	7.06e-05	0.000401	CcSEcCtD
Buprenorphine—Abdominal pain—Doxorubicin—ovarian cancer	7.02e-05	0.000399	CcSEcCtD
Buprenorphine—Body temperature increased—Doxorubicin—ovarian cancer	7.02e-05	0.000399	CcSEcCtD
Buprenorphine—Asthenia—Epirubicin—ovarian cancer	6.89e-05	0.000391	CcSEcCtD
Buprenorphine—Pruritus—Epirubicin—ovarian cancer	6.79e-05	0.000386	CcSEcCtD
Buprenorphine—Diarrhoea—Epirubicin—ovarian cancer	6.57e-05	0.000373	CcSEcCtD
Buprenorphine—Hypersensitivity—Doxorubicin—ovarian cancer	6.55e-05	0.000372	CcSEcCtD
Buprenorphine—Asthenia—Doxorubicin—ovarian cancer	6.38e-05	0.000362	CcSEcCtD
Buprenorphine—Dizziness—Epirubicin—ovarian cancer	6.35e-05	0.000361	CcSEcCtD
Buprenorphine—Pruritus—Doxorubicin—ovarian cancer	6.29e-05	0.000357	CcSEcCtD
Buprenorphine—Vomiting—Epirubicin—ovarian cancer	6.11e-05	0.000347	CcSEcCtD
Buprenorphine—Diarrhoea—Doxorubicin—ovarian cancer	6.08e-05	0.000345	CcSEcCtD
Buprenorphine—Rash—Epirubicin—ovarian cancer	6.05e-05	0.000344	CcSEcCtD
Buprenorphine—Dermatitis—Epirubicin—ovarian cancer	6.05e-05	0.000343	CcSEcCtD
Buprenorphine—Headache—Epirubicin—ovarian cancer	6.02e-05	0.000342	CcSEcCtD
Buprenorphine—Dizziness—Doxorubicin—ovarian cancer	5.88e-05	0.000334	CcSEcCtD
Buprenorphine—Nausea—Epirubicin—ovarian cancer	5.7e-05	0.000324	CcSEcCtD
Buprenorphine—Vomiting—Doxorubicin—ovarian cancer	5.65e-05	0.000321	CcSEcCtD
Buprenorphine—Rash—Doxorubicin—ovarian cancer	5.6e-05	0.000318	CcSEcCtD
Buprenorphine—Dermatitis—Doxorubicin—ovarian cancer	5.6e-05	0.000318	CcSEcCtD
Buprenorphine—Headache—Doxorubicin—ovarian cancer	5.57e-05	0.000316	CcSEcCtD
Buprenorphine—Nausea—Doxorubicin—ovarian cancer	5.28e-05	0.0003	CcSEcCtD
Buprenorphine—ABCB1—lymph node—ovarian cancer	5.21e-05	0.0054	CbGeAlD
Buprenorphine—OPRM1—Signaling Pathways—CAV1—ovarian cancer	7.1e-06	0.00021	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CYP1B1—ovarian cancer	7.01e-06	0.000208	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—MAPK1—ovarian cancer	6.97e-06	0.000207	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—EGFR—ovarian cancer	6.97e-06	0.000207	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PIK3CD—ovarian cancer	6.95e-06	0.000206	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—PIK3CA—ovarian cancer	6.9e-06	0.000205	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—FASN—ovarian cancer	6.87e-06	0.000204	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ESR1—ovarian cancer	6.84e-06	0.000203	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—ERBB2—ovarian cancer	6.77e-06	0.000201	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—SLC5A5—ovarian cancer	6.76e-06	0.000201	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL6ST—ovarian cancer	6.73e-06	0.0002	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PIK3CD—ovarian cancer	6.72e-06	0.000199	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—FASN—ovarian cancer	6.71e-06	0.000199	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CG—ovarian cancer	6.71e-06	0.000199	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—CAV1—ovarian cancer	6.69e-06	0.000198	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	6.69e-06	0.000198	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PIK3CB—ovarian cancer	6.68e-06	0.000198	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MTOR—ovarian cancer	6.68e-06	0.000198	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ABCB1—ovarian cancer	6.67e-06	0.000198	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—PIK3CA—ovarian cancer	6.66e-06	0.000198	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CG—ovarian cancer	6.65e-06	0.000197	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PTEN—ovarian cancer	6.62e-06	0.000196	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—SLC5A5—ovarian cancer	6.6e-06	0.000196	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—KRAS—ovarian cancer	6.58e-06	0.000195	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—YAP1—ovarian cancer	6.57e-06	0.000195	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—TYMS—ovarian cancer	6.55e-06	0.000194	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—SLC2A1—ovarian cancer	6.53e-06	0.000194	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	6.5e-06	0.000193	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CG—ovarian cancer	6.46e-06	0.000192	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—APC—ovarian cancer	6.46e-06	0.000192	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—NRAS—ovarian cancer	6.46e-06	0.000192	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CXCL8—ovarian cancer	6.42e-06	0.000191	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	6.39e-06	0.00019	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—HRAS—ovarian cancer	6.38e-06	0.000189	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—SLC2A1—ovarian cancer	6.37e-06	0.000189	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—FASN—ovarian cancer	6.32e-06	0.000187	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CDKN1B—ovarian cancer	6.27e-06	0.000186	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—FASN—ovarian cancer	6.27e-06	0.000186	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CYP1B1—ovarian cancer	6.26e-06	0.000186	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	6.22e-06	0.000184	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—SLC5A5—ovarian cancer	6.22e-06	0.000184	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—AKT1—ovarian cancer	6.2e-06	0.000184	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—MAPK3—ovarian cancer	6.19e-06	0.000184	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	6.19e-06	0.000184	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—SLC5A5—ovarian cancer	6.16e-06	0.000183	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CASP3—ovarian cancer	6.15e-06	0.000182	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL2—ovarian cancer	6.14e-06	0.000182	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CYP1B1—ovarian cancer	6.11e-06	0.000181	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—IL6—ovarian cancer	6.11e-06	0.000181	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CG—ovarian cancer	6.09e-06	0.000181	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PIK3CB—ovarian cancer	6.06e-06	0.00018	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—PIK3CA—ovarian cancer	6.05e-06	0.000179	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—SLC2A1—ovarian cancer	6e-06	0.000178	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCND1—ovarian cancer	5.98e-06	0.000177	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—SLC2A1—ovarian cancer	5.95e-06	0.000177	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—ERBB2—ovarian cancer	5.94e-06	0.000176	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CTNNB1—ovarian cancer	5.93e-06	0.000176	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CD—ovarian cancer	5.9e-06	0.000175	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—MAPK1—ovarian cancer	5.89e-06	0.000175	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—EGFR—ovarian cancer	5.89e-06	0.000175	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PIK3CB—ovarian cancer	5.86e-06	0.000174	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MTOR—ovarian cancer	5.86e-06	0.000174	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CD—ovarian cancer	5.84e-06	0.000173	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	5.83e-06	0.000173	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MMP9—ovarian cancer	5.81e-06	0.000172	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PTEN—ovarian cancer	5.78e-06	0.000171	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ABCB1—ovarian cancer	5.77e-06	0.000171	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CYP1B1—ovarian cancer	5.76e-06	0.000171	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	5.71e-06	0.00017	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CYP1B1—ovarian cancer	5.71e-06	0.000169	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CD—ovarian cancer	5.68e-06	0.000169	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—TYMS—ovarian cancer	5.67e-06	0.000168	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—AKT1—ovarian cancer	5.63e-06	0.000167	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CXCL8—ovarian cancer	5.63e-06	0.000167	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—PIK3CA—ovarian cancer	5.63e-06	0.000167	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—HRAS—ovarian cancer	5.6e-06	0.000166	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—KRAS—ovarian cancer	5.56e-06	0.000165	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	5.55e-06	0.000165	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.52e-06	0.000164	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CDKN1B—ovarian cancer	5.5e-06	0.000163	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—AKT1—ovarian cancer	5.44e-06	0.000161	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PPP2R1A—ovarian cancer	5.42e-06	0.000161	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CASP3—ovarian cancer	5.39e-06	0.00016	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL2—ovarian cancer	5.38e-06	0.00016	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CD—ovarian cancer	5.36e-06	0.000159	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—IL6—ovarian cancer	5.36e-06	0.000159	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—FASN—ovarian cancer	5.35e-06	0.000159	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CAV1—ovarian cancer	5.28e-06	0.000157	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—SLC5A5—ovarian cancer	5.27e-06	0.000156	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCND1—ovarian cancer	5.25e-06	0.000156	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTEN—ovarian cancer	5.23e-06	0.000155	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—VEGFA—ovarian cancer	5.22e-06	0.000155	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CTNNB1—ovarian cancer	5.2e-06	0.000154	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—STAT3—ovarian cancer	5.16e-06	0.000153	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ABCB1—ovarian cancer	5.15e-06	0.000153	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NRAS—ovarian cancer	5.15e-06	0.000153	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CB—ovarian cancer	5.14e-06	0.000152	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—PIK3CA—ovarian cancer	5.11e-06	0.000152	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	5.11e-06	0.000151	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CB—ovarian cancer	5.09e-06	0.000151	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MMP9—ovarian cancer	5.09e-06	0.000151	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—SLC2A1—ovarian cancer	5.09e-06	0.000151	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—YAP1—ovarian cancer	5.07e-06	0.00015	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PTEN—ovarian cancer	5.06e-06	0.00015	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—TYMS—ovarian cancer	5.06e-06	0.00015	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	5.06e-06	0.00015	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.04e-06	0.000149	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ERBB2—ovarian cancer	5.02e-06	0.000149	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.98e-06	0.000148	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MTOR—ovarian cancer	4.95e-06	0.000147	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CB—ovarian cancer	4.95e-06	0.000147	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—TYMS—ovarian cancer	4.94e-06	0.000147	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—AKT1—ovarian cancer	4.94e-06	0.000147	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MAPK3—ovarian cancer	4.93e-06	0.000146	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP1B1—ovarian cancer	4.88e-06	0.000145	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CG—ovarian cancer	4.81e-06	0.000143	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MYC—ovarian cancer	4.8e-06	0.000142	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CXCL8—ovarian cancer	4.76e-06	0.000141	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ABCB1—ovarian cancer	4.74e-06	0.000141	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—HRAS—ovarian cancer	4.73e-06	0.00014	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ABCB1—ovarian cancer	4.7e-06	0.000139	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MAPK1—ovarian cancer	4.7e-06	0.000139	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EGFR—ovarian cancer	4.69e-06	0.000139	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PIK3CA—ovarian cancer	4.67e-06	0.000139	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CB—ovarian cancer	4.67e-06	0.000139	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—TYMS—ovarian cancer	4.66e-06	0.000138	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CDKN1B—ovarian cancer	4.65e-06	0.000138	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—TYMS—ovarian cancer	4.62e-06	0.000137	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—AKT1—ovarian cancer	4.6e-06	0.000136	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VEGFA—ovarian cancer	4.57e-06	0.000136	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CAV1—ovarian cancer	4.57e-06	0.000136	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CASP3—ovarian cancer	4.56e-06	0.000135	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL2—ovarian cancer	4.55e-06	0.000135	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—STAT3—ovarian cancer	4.53e-06	0.000134	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—IL6—ovarian cancer	4.53e-06	0.000134	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NRAS—ovarian cancer	4.52e-06	0.000134	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTEN—ovarian cancer	4.44e-06	0.000132	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—KRAS—ovarian cancer	4.43e-06	0.000132	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCND1—ovarian cancer	4.43e-06	0.000132	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTEN—ovarian cancer	4.4e-06	0.000131	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CTNNB1—ovarian cancer	4.39e-06	0.00013	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.37e-06	0.00013	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MAPK3—ovarian cancer	4.33e-06	0.000128	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	4.33e-06	0.000128	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MMP9—ovarian cancer	4.3e-06	0.000128	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.3e-06	0.000128	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PTEN—ovarian cancer	4.28e-06	0.000127	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CD—ovarian cancer	4.22e-06	0.000125	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MYC—ovarian cancer	4.21e-06	0.000125	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—AKT1—ovarian cancer	4.18e-06	0.000124	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CG—ovarian cancer	4.16e-06	0.000123	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—FASN—ovarian cancer	4.13e-06	0.000123	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MAPK1—ovarian cancer	4.12e-06	0.000122	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EGFR—ovarian cancer	4.12e-06	0.000122	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CAV1—ovarian cancer	4.08e-06	0.000121	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PIK3CA—ovarian cancer	4.07e-06	0.000121	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SLC5A5—ovarian cancer	4.06e-06	0.000121	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTEN—ovarian cancer	4.03e-06	0.00012	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ABCB1—ovarian cancer	4.02e-06	0.000119	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CAV1—ovarian cancer	3.98e-06	0.000118	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—TYMS—ovarian cancer	3.94e-06	0.000117	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TP53—ovarian cancer	3.94e-06	0.000117	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SLC2A1—ovarian cancer	3.93e-06	0.000116	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.9e-06	0.000116	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—KRAS—ovarian cancer	3.89e-06	0.000115	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VEGFA—ovarian cancer	3.87e-06	0.000115	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—STAT3—ovarian cancer	3.83e-06	0.000114	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NRAS—ovarian cancer	3.82e-06	0.000113	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—AKT1—ovarian cancer	3.82e-06	0.000113	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—HRAS—ovarian cancer	3.77e-06	0.000112	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP1B1—ovarian cancer	3.76e-06	0.000112	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CAV1—ovarian cancer	3.75e-06	0.000111	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CAV1—ovarian cancer	3.72e-06	0.00011	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CG—ovarian cancer	3.72e-06	0.00011	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PIK3CA—ovarian cancer	3.69e-06	0.00011	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CB—ovarian cancer	3.68e-06	0.000109	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CD—ovarian cancer	3.66e-06	0.000109	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MAPK3—ovarian cancer	3.66e-06	0.000108	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CG—ovarian cancer	3.63e-06	0.000108	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL6—ovarian cancer	3.61e-06	0.000107	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PIK3CA—ovarian cancer	3.57e-06	0.000106	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MYC—ovarian cancer	3.56e-06	0.000106	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.55e-06	0.000105	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MAPK1—ovarian cancer	3.48e-06	0.000103	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EGFR—ovarian cancer	3.48e-06	0.000103	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TP53—ovarian cancer	3.46e-06	0.000103	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	3.42e-06	0.000101	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CG—ovarian cancer	3.39e-06	0.0001	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	3.34e-06	9.9e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—AKT1—ovarian cancer	3.33e-06	9.87e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—HRAS—ovarian cancer	3.31e-06	9.8e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—KRAS—ovarian cancer	3.29e-06	9.75e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CD—ovarian cancer	3.27e-06	9.69e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CB—ovarian cancer	3.19e-06	9.46e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CD—ovarian cancer	3.19e-06	9.46e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTEN—ovarian cancer	3.18e-06	9.44e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CAV1—ovarian cancer	3.18e-06	9.43e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL6—ovarian cancer	3.16e-06	9.38e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CA—ovarian cancer	3.13e-06	9.29e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CA—ovarian cancer	3.11e-06	9.21e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ABCB1—ovarian cancer	3.1e-06	9.19e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TYMS—ovarian cancer	3.04e-06	9.03e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.04e-06	9.01e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CA—ovarian cancer	3.02e-06	8.96e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—AKT1—ovarian cancer	3.02e-06	8.95e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	3e-06	8.91e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CD—ovarian cancer	2.98e-06	8.83e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TP53—ovarian cancer	2.92e-06	8.66e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—AKT1—ovarian cancer	2.92e-06	8.66e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CG—ovarian cancer	2.89e-06	8.59e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CB—ovarian cancer	2.85e-06	8.44e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CA—ovarian cancer	2.85e-06	8.44e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—HRAS—ovarian cancer	2.79e-06	8.29e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CB—ovarian cancer	2.78e-06	8.24e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTEN—ovarian cancer	2.76e-06	8.18e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL6—ovarian cancer	2.67e-06	7.93e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	2.62e-06	7.77e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CB—ovarian cancer	2.6e-06	7.7e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—AKT1—ovarian cancer	2.56e-06	7.59e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CD—ovarian cancer	2.54e-06	7.55e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—AKT1—ovarian cancer	2.54e-06	7.53e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AKT1—ovarian cancer	2.47e-06	7.32e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTEN—ovarian cancer	2.46e-06	7.3e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CAV1—ovarian cancer	2.45e-06	7.28e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTEN—ovarian cancer	2.4e-06	7.12e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—AKT1—ovarian cancer	2.33e-06	6.9e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTEN—ovarian cancer	2.26e-06	6.71e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CA—ovarian cancer	2.24e-06	6.66e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTEN—ovarian cancer	2.24e-06	6.65e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.23e-06	6.63e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CB—ovarian cancer	2.22e-06	6.58e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.96e-06	5.83e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CA—ovarian cancer	1.94e-06	5.77e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTEN—ovarian cancer	1.92e-06	5.69e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—AKT1—ovarian cancer	1.83e-06	5.44e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CA—ovarian cancer	1.74e-06	5.15e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.71e-06	5.08e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.69e-06	5.02e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	1.6e-06	4.74e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AKT1—ovarian cancer	1.59e-06	4.71e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CA—ovarian cancer	1.58e-06	4.69e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTEN—ovarian cancer	1.48e-06	4.39e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AKT1—ovarian cancer	1.42e-06	4.21e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AKT1—ovarian cancer	1.38e-06	4.1e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CA—ovarian cancer	1.35e-06	4.01e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AKT1—ovarian cancer	1.3e-06	3.87e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AKT1—ovarian cancer	1.29e-06	3.83e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AKT1—ovarian cancer	1.1e-06	3.28e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.04e-06	3.1e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AKT1—ovarian cancer	8.53e-07	2.53e-05	CbGpPWpGaD
